US Stock Insider Trading | Silvergate disclosed 5 insider transactions on February 17

K-LinePoet · 2026-02-20T20:07:44+00:00

On February 17, 2026, Insulet Corporation disclosed that several executives sold shares on February 12, 2026, with total transactions exceeding $2 million, indicating active insider trading. The company focuses on the development and sale of insulin delivery systems to advance treatment for diabetes patients.

K-LinePoet

2026-02-20 20:07:44

Abstract generation in progress

On February 17, 2026, Insulet Corporation (PODD) disclosed five insider transactions. Executive Benjamin Eric sold 2,887 shares on February 12, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 17, 2026	Executive	Laetitia Cousin	February 12, 2026	Sell	564	240.82	$135,800
February 17, 2026	Executive	Lauren Budden	February 12, 2026	Sell	622	240.82	$149,800
February 17, 2026	Executive	Prem Singh	February 12, 2026	Sell	861	240.82	$207,300
February 17, 2026	Executive	John W. Kapples	February 12, 2026	Sell	1,929	240.82	$464,500
February 17, 2026	Executive	Eric Benjamin	February 12, 2026	Sell	2,887	240.82	$695,200
January 6, 2026	Executive	Laetitia Cousin	January 2, 2026	Sell	140	282.92	$39,600
January 6, 2026	Director	Robert Luther Huffines	December 31, 2025	Buy	50	284.24	$14,400
December 16, 2025	Director	Wayne A.I. Frederick	December 15, 2025	Sell	1,851	293.09	$542,500
December 8, 2025	Director	Timothy C. Stonesifer	December 5, 2025	Buy	962	311.73	$299,900
September 9, 2025	Executive	Laetitia Cousin	September 8, 2025	Buy	541	276.36	$149,500

[Company Information]

Insulet Corporation, founded in 2000 and based in Delaware, primarily develops, manufactures, and sells its proprietary insulin delivery systems for insulin-dependent diabetics. The Omnipod platform includes the Omnipod 5 automated insulin delivery system, Omnipod DASH insulin management system, Omnipod insulin management system, and the latest innovation, Omnipod G0TM, which received FDA approval in 2023. The company also produces Pods for Amgen, used in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta that helps reduce infection risk after intensive chemotherapy.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes